Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 28, 2014; 20(44): 16714-16720
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16714
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16714
Table 1 Patient characteristics
Variables | n = 78 |
Age (yr) | 66.7 ± 10.3 |
Gender (male/female) | 63/15 |
HBs-Ag (+/-) | 26/52 |
HCV-Ab (+/-) | 21/57 |
Alcohol abuse (+/-) | 10/68 |
NASH (+/-) | 14/64 |
Diabetes mellitus (+/-) | 25/73 |
Hyperlipidemia (+/-) | 18/60 |
Platelets (× 104/mm3) | 16.6 ± 7.0 |
Prothrombin time (INR) | 1.05 ± 0.11 |
Albumin (g/dL) | 4.0 ± 0.6 |
Total bilirubin (mg/dL) | 0.8 ± 0.3 |
Cholinesterase (U/L) | 248 ± 70 |
Tumor size (cm) | 49.6 ± 36.9 |
Tumor number | 1.2 ± 0.5 |
Tumor vascular invasion (+/-) | 21/57 |
Ishak classification 0/1/2/3/4/5/6 | 14/11/8/18/4/13/10 |
MELD score | 5.3 ± 1.3 |
CTP score | 5.2 ± 0.2 |
ICG R15 (%) | 11.6 ± 6.0 |
Table 2 Correlations between the degree of liver fibrosis and quantitative indices for liver functional reserve
r | P value | |
ICG R15 | 0.330 | 0.003 |
HH15 | 0.272 | 0.016 |
LHL15 | -0.198 | 0.083 |
HC | -0.598 | < 0.00001 |
Table 3 Correlations between quantitative indices for liver functional reserve and conventional liver function tests
ICG R15 | LHL 15 | HH 15 | HC | |||||
r | P value | r | P value | r | P value | r | P value | |
Platelets (× 104/mm3) | -0.160 | 0.161 | 0.235 | 0.038 | -0.185 | 0.105 | 0.348 | 0.002 |
Prothrombin time (INR) | 0.082 | 0.473 | -0.122 | 0.289 | -0.016 | 0.888 | -0.287 | 0.011 |
Albumin (g/dL) | -0.044 | 0.703 | 0.263 | 0.020 | -0.123 | 0.285 | 0.233 | 0.040 |
Total bilirubin (mg/dL) | 0.204 | 0.073 | -0.217 | 0.057 | 0.289 | 0.010 | -0.345 | 0.002 |
Cholinesterase (U/L) | -0.113 | 0.324 | 0.221 | 0.052 | -0.263 | 0.020 | 0.419 | 0.0001 |
Table 4 Univariate and multivariate analyses of variables predictive of severe fibrosis
Variable | Severe fibrosis | P value | ||
Yes (n = 27) | No (n = 51) | Univariate analysis | Multivariate analysis | |
Gender (male/female) | 23/4 | Nov-40 | 0.474 | |
Age (yr) | 66.5 ± 10.0 | 66.8 ± 10.5 | 0.950 | |
HBs-Ag (+/-) | 10/17 | 16/35 | 0.616 | |
HCV-Ab (+/-) | 10/17 | 11/40 | 0.145 | |
Alcohol abuse (+/-) | 2/25 | 8/43 | 0.301 | |
NASH (+/-) | 4/23 | 10/41 | 0.602 | |
Platelets (× 104/mm3) | 12.7 ± 3.9 | 18.7 ± 7.4 | < 0.001 | 0.096 |
Prothrombin time (INR) | 1.09 ± 0.12 | 1.03 ± 0.10 | 0.032 | 0.223 |
Albumin (g/dL) | 4.0 ± 0.6 | 4.1 ± 0.6 | 0.388 | |
Total bilirubin (mg/dL) | 0.9 ± 0.3 | 0.7 ± 0.3 | 0.001 | 0.354 |
Cholinesterase (U/L) | 234 ± 75 | 255 ± 68 | 0.229 | |
Tumor size (cm) | 3.5 ± 1.6 | 5.7 ± 4.2 | 0.042 | 0.137 |
Tumor number | 1.1 ± 0.4 | 1.2 ± 0.6 | 0.543 | |
Tumor vascular invasion (+/-) | 5/22 | 16/35 | 0.226 | |
MELD score | 5.8 ± 1.1 | 5.1 ± 1.2 | 0.009 | |
CTP score | 5.3 ± 0.6 | 5.2 ± 0.4 | 0.685 | |
ICG R15 (%) | 14.3 ± 6.1 | 10.2 ± 5.5 | 0.019 | 0.183 |
LHL 15 | 0.901 ± 0.044 | 0.935 ± 0.024 | 0.042 | 0.041 |
HH 15 | 0.648 ± 0.068 | 0.556 ± 0.067 | 0.004 | 0.053 |
HC | 263.3 ± 90.4 | 381.1 ± 96.7 | < 0.001 | 0.030 |
- Citation: Taniguchi M, Okizaki A, Watanabe K, Imai K, Uchida K, Einama T, Shuke N, Miyokawa N, Furukawa H. Hepatic clearance measured with 99mTc-GSA single-photon emission computed tomography to estimate liver fibrosis. World J Gastroenterol 2014; 20(44): 16714-16720
- URL: https://www.wjgnet.com/1007-9327/full/v20/i44/16714.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i44.16714